Editas Medicine, Inc. (NASDAQ:EDIT) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Despite an already strong run, Editas Medicine, Inc. (NASDAQ:EDIT) shares have been powering on, with a gain of 26% in the last thirty days. Not all shareholders will be feeling jubilant, since the share price is still down a very disappointing 21% in the last twelve months.
Even after such a large jump in price, Editas Medicine’s price-to-sales (or “P/S”) ratio of 6.4x might still make it look like a buy right now compared to the Biotechs industry in the United States, where around half of the companies have P/S ratios above 9.4x and even P/S above 67x are quite common. Although, it’s not wise to just take the P/S at face value as there may be an explanation why it’s limited.
